The treatment represents a new option for patients whose symptoms continue to recur despite conventional medical treatment ...
Colorectal cancer rates in the United States are rising across a much wider range of ages than previously recognized, ...
PolyPid's SHIELD II Phase 3 data showed clinically meaningful reductions in surgical site infections. Read why I rate PYPD ...
Recursion highlights promising clinical data for REC-4881 and REC-1245, beats Q3 earnings estimates and extends its cash runway into 2029 through disciplined spending.
The examination is over, and you have finished changing. At the consultation, you are told, "We found a polyp, so we removed ...
Background Duodenal cancer is a leading cause of cancer-related mortality in familial adenomatous polyposis (FAP), yet the ...
Radiology reports can include words like lesion, nodule, cyst, enhancement or correlate clinically. Learn what they may mean ...
Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.
President and Chief Executive Officer - Najat Khan ...
Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial ...
Stephanie Nolen saw nine women bring new babies safely into the world while reporting this story in labor wards in the north ...
Recursion’s Q3 2026 earnings call highlighted REC-4881 FAP data, REC-1245 tumor responses, $749 million in pro forma cash and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results